
    
      Single Ascending Dose (SAD), Double-Blind, Placebo Controlled Study.

      To evaluate the safety and tolerability of single ascending doses of CTI-1601 in subjects
      with Friedreich's ataxia.

      Secondary Objectives:

        1. To evaluate the pharmacokinetics (PK) of CTI-1601 following increasing single doses of
           subcutaneously (SC) administered CTI-1601.

        2. To evaluate the pharmacodynamics (PD) of CTI-1601 following increasing single doses of
           SC administered CTI-1601.

      CTI-1601 or Placebo - Dose/Mode of Administration: Single Dose/Subcutaneous
    
  